Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment interruptions news

Show

From To
HIV-positive participant in vaccine study passes virus to sexual partner during treatment interruption

An HIV-positive man transmitted HIV to his sexual partner after interrupting antiretroviral therapy as part of a research study into a therapeutic vaccine, French scientists reported in

Published
01 March 2019
By
Roger Pebody
Atripla or efavirenz plus Truvada failed one in 16 people in first year

Estimates of how often people on antiretroviral therapy (ART) do not remain virally undetectable are important both in order to gauge the potency of ART, and to

Published
21 January 2019
By
Gus Cairns
Viral load in semen rapidly rebounds to infectious levels during HIV treatment breaks

Viral load rebounds rapidly in semen to potentially infectious levels following interruption of combination antiretroviral therapy (cART), according to French research published in AIDS.Increases in viral load in both

Published
14 November 2018
By
Michael Carter
One in nine people may be able to control their viral load after stopping treatment, US study finds

A US collaboration that pooled data from 14 scientific studies containing between them more than 600 HIV-positive people has found that 67 of them were able to

Published
16 August 2018
By
Gus Cairns
VRC01 antibody can delay but not prevent viral rebound after interruption of early treatment

A broadly neutralising antibody modestly delayed the resurgence of viral replication following interruption of antiretroviral therapy (ART) started during very early infection, but all study participants ultimately experienced

Published
02 August 2017
By
Liz Highleyman
Researchers report case of bone marrow transplant patient off ART for 288 days without HIV rebound

An HIV-positive bone marrow transplant recipient at the Mayo Clinic experienced prolonged viral remission lasting nearly 10 months – longer than the so-called Boston patients – after interrupting

Published
06 March 2017
By
Liz Highleyman
VRC01 antibody delays but does not prevent HIV rebound after antiretroviral treatment interruption

VRC01, a broadly neutralising antibody targeting HIV's CD4 binding site, was able to modestly delay the return of viral replication following interruption of antiretroviral therapy (ART), according to

Published
08 April 2016
By
Liz Highleyman
People taking a large number of non-HIV-related medications more likely to stop or change HIV drugs

HIV-positive patients who are taking a large number of medications for the treatment of non-HIV-related conditions are at increased risk of stopping or changing their antiretroviral therapy (ART),

Published
27 January 2016
By
Michael Carter
Post-treatment control of HIV appears rare, biomarkers may help predict viral rebound

Only four individuals out of nearly 5000 people receiving care at US military health facilities were found to exhibit immune control of HIV after starting antiretroviral therapy

Published
04 November 2015
By
Liz Highleyman
Benefits of early HIV treatment are clear, but issues raised by START and D:A:D remain unresolved

The long-running controversy over when to start antiretroviral therapy (ART) has been definitively answered, but research is still needed to fully understand the implications of the large START

Published
23 October 2015
By
Liz Highleyman
← First12345...9Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.